Spots Global Cancer Trial Database for A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Official Title: A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions
Study ID: NCT05567185
Interventions
Study Description
Brief Summary: The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
St Marianna University Hospital, Kanagawa, , Japan
Osaka International Cancer Institute, Osaka, , Japan
Toyama University Hospital, Toyama-shi, , Japan
University of Tsukuba Hospital, Tsukuba, , Japan
Contact Details
Name: Janssen Pharmaceutical K.K., Japan Clinical Trial
Affiliation: Janssen Pharmaceutical K.K.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
